Phaseline

Companies › 7 Hills Pharma

7 Hills Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Alintegimod
α4β7 integrin antagonist
ITGA4, ITGB7Phase 1Advanced CancerDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06362369AlintegimodPhase 1Advanced CancerOncologyDec 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

ITGA4 (1) ITGB7 (1)

Companies with the same targets

Takeda Roche Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Gilead Sciences

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.